Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Halank

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
European Heart Journal|April 29, 2022
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS studyLuca Valerio, Anna C Mavromanoli, Stefano Barco, et al.
Respiratory Medicine|February 4, 2021
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registryHossein-Ardeschir Ghofrani, Miguel-Angel Gomez Sanchez, Marc Humbert, et al.
The European Respiratory Journal|October 22, 2021
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registryMarius M Hoeper, Christine Pausch, Ekkehard Grünig, et al.
Respiratory Medicine|January 10, 2021
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registryMarius M Hoeper, Miguel-Angel Gomez Sanchez, Marc Humbert, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 17, 2022
Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysisMarius M Hoeper, Christine Pausch, Karen M Olsson, et al.
The European Respiratory Journal|November 5, 2021
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertensionMarius M Hoeper, Christine Pausch, Karen M Olsson, et al.
Rheumatology (Oxford, England)|July 18, 2023
Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysisOliver Distler, Christian Ofner, Dörte Huscher, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 4, 2022
Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysisStephan Rosenkranz, Christine Pausch, John G Coghlan, et al.
American Journal of Respiratory and Critical Care Medicine|August 7, 2025
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry AnalysisAthiththan Yogeswaran, Paul M Hassoun, Khaled Saleh, et al.
The Lancet. Respiratory Medicine|July 1, 2022
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysisMarius M Hoeper, Krit Dwivedi, Christine Pausch, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
European Heart Journal|April 29, 2022
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS studyLuca Valerio, Anna C Mavromanoli, Stefano Barco, et al.
Respiratory Medicine|February 4, 2021
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registryHossein-Ardeschir Ghofrani, Miguel-Angel Gomez Sanchez, Marc Humbert, et al.
The European Respiratory Journal|October 22, 2021
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registryMarius M Hoeper, Christine Pausch, Ekkehard Grünig, et al.
Respiratory Medicine|January 10, 2021
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registryMarius M Hoeper, Miguel-Angel Gomez Sanchez, Marc Humbert, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 17, 2022
Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysisMarius M Hoeper, Christine Pausch, Karen M Olsson, et al.
The European Respiratory Journal|November 5, 2021
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertensionMarius M Hoeper, Christine Pausch, Karen M Olsson, et al.
Rheumatology (Oxford, England)|July 18, 2023
Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysisOliver Distler, Christian Ofner, Dörte Huscher, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 4, 2022
Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysisStephan Rosenkranz, Christine Pausch, John G Coghlan, et al.
American Journal of Respiratory and Critical Care Medicine|August 7, 2025
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry AnalysisAthiththan Yogeswaran, Paul M Hassoun, Khaled Saleh, et al.
The Lancet. Respiratory Medicine|July 1, 2022
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysisMarius M Hoeper, Krit Dwivedi, Christine Pausch, et al.
Pageof 14